{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=42", "query": { "condition": "Head and Neck Squamous Cell Carcinomas", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 1529, "total_pages": 153, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+and+Neck+Squamous+Cell+Carcinomas&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T03:17:18.141Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00660218", "title": "A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Squamous Cell" ], "interventions": [ { "name": "paclitaxel poliglumex", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "radiation therapy (IMRT or 3D-CRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "State University of New York - Upstate Medical University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2008-03", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2021-11-08", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 1, "location_summary": "Syracuse, New York", "locations": [ { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00660218" }, { "nct_id": "NCT04929392", "title": "Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Carcinoma", "Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Endoscopic Biopsy", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Lenvatinib Mesylate", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-01-25", "completion_date": "2027-04-25", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04929392" }, { "nct_id": "NCT04590963", "title": "Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Monalizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 370, "start_date": "2020-10-02", "completion_date": "2026-09-24", "has_results": true, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 17, "location_summary": "Tucson, Arizona • Chicago, Illinois • Westwood, Kansas + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04590963" }, { "nct_id": "NCT04210115", "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma (ESCC)", "Gastroesophageal Junction Carcinoma (GEJC)", "Esophageal Adenocarcinoma (EAC)" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "radiotherapy", "type": "RADIATION" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "levoleucovorin", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 703, "start_date": "2020-02-28", "completion_date": "2026-06-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 19, "location_summary": "Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04210115" }, { "nct_id": "NCT00185835", "title": "Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer", "Carcinoma, Squamous Cell" ], "interventions": [ { "name": "ZD-1839", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2002-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-03-29", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00185835" }, { "nct_id": "NCT01345682", "title": "LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Neoplasms", "Carcinoma, Squamous Cell" ], "interventions": [ { "name": "Afatinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 483, "start_date": "2012-01-05", "completion_date": "2016-12-06", "has_results": true, "last_update_posted_date": "2018-02-15", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 8, "location_summary": "Harvey, Illinois • Peoria, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Harvey", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01345682" }, { "nct_id": "NCT02388932", "title": "Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage III Hypopharyngeal Squamous Cell Carcinoma", "Stage III Laryngeal Squamous Cell Carcinoma", "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage III Oral Cavity Squamous Cell Carcinoma", "Stage III Oropharyngeal Squamous Cell Carcinoma", "Stage IVA Hypopharyngeal Squamous Cell Carcinoma", "Stage IVA Laryngeal Squamous Cell Carcinoma", "Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVA Oral Cavity Squamous Cell Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma", "Stage IVB Hypopharyngeal Squamous Cell Carcinoma", "Stage IVB Laryngeal Squamous Cell Carcinoma", "Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVB Oral Cavity Squamous Cell Carcinoma", "Stage IVB Oropharyngeal Squamous Cell Carcinoma", "Stage IVC Hypopharyngeal Squamous Cell Carcinoma", "Stage IVC Laryngeal Squamous Cell Carcinoma", "Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVC Oral Cavity Squamous Cell Carcinoma", "Stage IVC Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "DEVICE" }, { "name": "Computed Tomography", "type": "DEVICE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DEVICE", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2015-03-03", "completion_date": "2017-02-06", "has_results": true, "last_update_posted_date": "2019-01-24", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02388932" }, { "nct_id": "NCT03195699", "title": "Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Non Small Cell Lung Cancer", "Hepatocellular Cancer", "Colorectal Cancer", "Gastric Adenocarcinoma", "Melanoma", "Advanced Cancer" ], "interventions": [ { "name": "TTI-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tvardi Therapeutics, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2017-11-15", "completion_date": "2024-06-24", "has_results": false, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 2, "location_summary": "Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03195699" }, { "nct_id": "NCT04989387", "title": "Study of INCA 0186 in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Gastrointestinal (GI) Malignancies" ], "interventions": [ { "name": "INCA00186", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "INCB106385", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 57, "start_date": "2021-10-04", "completion_date": "2024-09-19", "has_results": false, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 8, "location_summary": "Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04989387" }, { "nct_id": "NCT05576974", "title": "A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Unknown Primary Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Pegsitacianine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 120, "start_date": "2024-04-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-22T03:17:18.141Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05576974" } ] }